DekaBank Deutsche Girozentrale Invests $534,000 in Altimmune, Inc. (NASDAQ:ALT)

DekaBank Deutsche Girozentrale purchased a new position in shares of Altimmune, Inc. (NASDAQ:ALT) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 45,000 shares of the company’s stock, valued at approximately $534,000.

Several other large investors also recently modified their holdings of ALT. State Street Corp increased its stake in shares of Altimmune by 2,407.5% during the 3rd quarter. State Street Corp now owns 3,398,856 shares of the company’s stock worth $43,403,000 after purchasing an additional 3,263,310 shares during the last quarter. BlackRock Inc. increased its stake in shares of Altimmune by 162.9% during the 2nd quarter. BlackRock Inc. now owns 3,664,274 shares of the company’s stock worth $12,935,000 after purchasing an additional 2,270,219 shares during the last quarter. Balyasny Asset Management LLC increased its stake in shares of Altimmune by 402.6% during the 3rd quarter. Balyasny Asset Management LLC now owns 1,037,662 shares of the company’s stock worth $13,251,000 after purchasing an additional 831,193 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Altimmune by 101.1% during the 2nd quarter. Geode Capital Management LLC now owns 969,861 shares of the company’s stock worth $3,424,000 after purchasing an additional 487,500 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in Altimmune by 28.9% in the 2nd quarter. Marshall Wace LLP now owns 2,059,290 shares of the company’s stock valued at $7,269,000 after buying an additional 462,160 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Analyst Upgrades and Downgrades

ALT has been the subject of a number of recent research reports. The Goldman Sachs Group initiated coverage on shares of Altimmune in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 price objective for the company. B. Riley reiterated a “buy” rating and issued a $20.00 price objective on shares of Altimmune in a research note on Thursday, March 28th. Finally, HC Wainwright reduced their price target on shares of Altimmune from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, April 1st.

Altimmune Price Performance

ALT opened at $7.55 on Tuesday. The company has a fifty day moving average price of $9.72 and a 200-day moving average price of $7.30. The firm has a market capitalization of $535.22 million, a P/E ratio of -4.58 and a beta of 0.05. Altimmune, Inc. has a one year low of $2.09 and a one year high of $14.84.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.